Malaria in depth.

Overview

Malaria is a life-threatening parasitic disease caused by Plasmodium parasites — single-celled protozoan parasites transmitted to humans through the bites of infected female Anopheles mosquitoes. Five Plasmodium species infect humans: P. falciparum (responsible for the vast majority of malaria deaths), P. vivax (the most geographically widespread species), P. malariae, P. ovale, and P. knowlesi (a primate malaria increasingly recognized in Southeast Asia).

The WHO World Malaria Report 2022 estimated 247 million malaria cases and 619,000 malaria deaths in 2021 — a dramatic increase from pre-COVID levels, partly attributable to COVID-19 service disruptions. Sub-Saharan Africa bears approximately 95% of the global malaria burden. Children under 5 years are the most vulnerable population, accounting for approximately 80% of malaria deaths in Africa. A child dies from malaria approximately every two minutes.

Despite the enormous burden, malaria is both preventable and treatable. Since 2000, global malaria mortality has been reduced by approximately 60% through scale-up of insecticide-treated bed nets, indoor residual spraying, rapid diagnostic tests, and artemisinin-based combination therapies. The WHO recommendation of two malaria vaccines — RTS,S/AS01 (Mosquirix) in 2021 and R21/Matrix-M in 2023 — represents a transformative addition to the malaria prevention toolkit, with rollout ongoing across African countries.

History & Origin

Malaria has afflicted humans since prehistoric times. The characteristic malarial fever pattern was described by Chinese physicians as early as 2700 BCE and by Hippocrates in 400 BCE. The Italian word "mal aria" (bad air) reflects the ancient observation that the disease was associated with marshy areas — where Anopheles mosquitoes breed.

Charles Louis Alphonse Laveran discovered the malaria parasite in 1880 — the first protozoan parasite shown to cause human disease, earning him the Nobel Prize in 1907. Ronald Ross demonstrated in 1897 that the malaria parasite was transmitted by Anopheles mosquitoes — earning him the Nobel Prize in 1902. Quinine, derived from the bark of the cinchona tree, was used to treat malaria for centuries before synthetic antimalarials were developed. Chloroquine, introduced in the 1940s, became the standard treatment until widespread resistance emerged in the 1970s–1980s. Artemisinin, derived from the plant Artemisia annua by Chinese scientist Tu Youyou (Nobel Prize 2015), revolutionized malaria treatment.

Transmission

Malaria is transmitted exclusively through the bites of infected female Anopheles mosquitoes. Anopheles mosquitoes are distinguished from Aedes and Culex mosquitoes by their resting posture (at an angle to the surface rather than parallel) and their peak biting activity at night (dusk to dawn).

• Mosquito-to-human: An infected female Anopheles injects sporozoites (the infectious stage) into the human bloodstream during a blood meal. Sporozoites migrate to the liver within minutes.
• Human-to-mosquito: When a mosquito bites a person with sexual-stage parasites (gametocytes) in the blood, it ingests these parasites and becomes infected. After 10–18 days (the extrinsic incubation period, temperature-dependent), sporozoites develop in the mosquito's salivary glands.
• Blood transfusion and needle sharing: Malaria can be transmitted through blood transfusions, organ transplants, or shared needles — rare but documented.
• Congenital malaria: Transmission from mother to fetus is possible but uncommon.
• NOT transmitted by: Casual contact, coughing, sneezing, or touching an infected person.

Symptom Timeline

The incubation period is 7–30 days depending on species: P. falciparum 7–14 days, P. vivax/ovale 12–17 days (or months for relapsing forms), P. malariae 18–40 days. Travelers who took incomplete or no prophylaxis may develop malaria weeks to months after returning from endemic areas.

Diagnosis

• Light microscopy (blood smear): Gold standard for malaria diagnosis. Thick blood smear for parasite detection (sensitivity); thin blood smear for species identification and parasite density quantification. Requires skilled microscopist; 2–3 smears from different time points for maximum sensitivity.
• Rapid Diagnostic Tests (RDTs): Immunochromatographic tests detecting malaria antigens — HRP2 (P. falciparum-specific) and pLDH (all species). Provide results in 15–20 minutes. Widely deployed in remote areas without microscopy. Sensitivity >95% for P. falciparum at parasitemias above clinical threshold.
• PCR: Most sensitive method, detects parasitemia below microscopy threshold. Used for epidemiological surveillance, mixed infection detection, and drug resistance genotyping. Not routinely available in endemic settings.
• Full Blood Count: Anemia (normocytic), thrombocytopenia, and elevated lactate dehydrogenase (LDH) are characteristic. In severe malaria: low blood glucose, elevated creatinine, elevated lactate.
• NEVER delay treatment in a patient with clinical malaria presentation while awaiting diagnostic results — P. falciparum can progress to severe disease within 24 hours.

Treatment

WHO recommends artemisinin-based combination therapies (ACTs) as the first-line treatment for uncomplicated P. falciparum malaria. The partner drug prevents resistance selection and treats residual parasites after artemisinin activity wanes.

Uncomplicated P. falciparum Malaria

• Artemether-lumefantrine (Coartem): Most widely used ACT globally
• Artesunate-amodiaquine: Preferred in West Africa
• Dihydroartemisinin-piperaquine (DHA-PPQ): Used in Asia and Africa
• Artesunate-mefloquine: Used in Southeast Asia

Severe Malaria

• IV/IM artesunate: First-line treatment — superior to quinine in reducing mortality (AQUAMAT and SEAQUAMAT trials). Given for minimum 24 hours until oral therapy tolerated.
• Supportive care: anticonvulsants for seizures; blood transfusion for severe anemia; correction of hypoglycemia; renal replacement therapy for kidney failure; mechanical ventilation for ARDS

P. vivax / P. ovale Malaria

• Chloroquine (where sensitive) + primaquine for 14 days (G6PD testing required before primaquine) to eliminate liver hypnozoites and prevent relapses
• Tafenoquine (Krintafel): single-dose alternative to 14-day primaquine; G6PD testing mandatory

Prevention & Vaccines

• RTS,S/AS01 (Mosquirix): WHO-recommended in 2021. First malaria vaccine deployed at scale in Africa. ~39% efficacy against clinical malaria in children. Requires 4-dose schedule. Deployed in Ghana, Kenya, Malawi, and expanding to additional countries.
• R21/Matrix-M (Oxford/Serum Institute): WHO-recommended in 2023. Phase 3 trials show 75–77% efficacy. Lower cost and higher manufacturing capacity than RTS,S. Multiple African countries proceeding with deployment.
• Insecticide-treated bed nets (ITNs): The single most impactful malaria prevention tool. Long-lasting insecticidal nets (LLINs) protect against night-biting Anopheles mosquitoes. Universal coverage campaigns distributed over 2 billion nets since 2000.
• Indoor Residual Spraying (IRS): Spraying insecticide on indoor walls and surfaces kills resting mosquitoes. Highly effective when coverage is high and mosquito susceptibility to insecticides maintained.
• Chemoprophylaxis for travelers: Atovaquone-proguanil (Malarone), mefloquine, or doxycycline; choice depends on destination resistance patterns. Consult a travel medicine specialist.
• Seasonal Malaria Chemoprevention (SMC): Monthly preventive antimalarial courses for children in the Sahel region of Africa during peak transmission season — highly effective.
• Intermittent Preventive Treatment in Pregnancy (IPTp): Monthly sulfadoxine-pyrimethamine during pregnancy reduces maternal malaria, low birth weight, and maternal mortality.

Global Impact

Malaria is concentrated in the world's most vulnerable populations. Sub-Saharan Africa bears approximately 95% of global malaria cases and deaths. Six countries account for more than half of all global malaria cases: Nigeria, Democratic Republic of Congo, Uganda, Mozambique, Angola, and Burkina Faso. The WHO World Malaria Report 2022 estimated 619,000 malaria deaths in 2021 — a reversal of years of decline partly attributable to COVID-19 disrupting malaria services.

The economic cost of malaria is immense. It is estimated to reduce economic growth in high-burden African countries by up to 1.3% per year. Beyond direct mortality, malaria causes significant morbidity — repeated episodes impair child development, educational attainment, and adult productivity. Malaria in pregnancy causes maternal anemia, low birth weight, and increased infant mortality.

Drug resistance threatens the gains made with ACTs. Partial artemisinin resistance, initially identified in Southeast Asia, has been documented in parts of Africa — a development of grave concern. If artemisinin resistance spreads widely in Africa, where treatment infrastructure is limited, the consequences could be catastrophic. WHO and research partners are accelerating next-generation antimalarial development to stay ahead of resistance.

Country-Specific Information

Nigeria: Nigeria has the world's highest malaria burden — approximately 27% of global malaria cases and 31% of global malaria deaths. An estimated 51 million Nigerians develop malaria each year. Children under 5 and pregnant women are most affected. The National Malaria Elimination Programme coordinates ITN distribution, IRS campaigns, and ACT deployment.

Democratic Republic of Congo (DRC): DRC has the second-highest malaria burden globally with an estimated 97 million cases annually. Malaria is the leading cause of morbidity and mortality in DRC. Ongoing conflict and humanitarian crises severely hamper malaria control efforts. DRC is a priority country for Global Fund and WHO malaria intervention scaling.

Uganda: Uganda has one of the highest malaria transmission intensities in the world, with perennial transmission across most of the country. Malaria accounts for 30–50% of outpatient visits and 15–20% of hospital admissions. Uganda was among the first countries to deploy the RTS,S vaccine pilot program.

Mozambique: Mozambique ranks among the highest-burden malaria countries. The country has made progress with ITN scale-up but faces challenges from climate-related flooding events that intensify mosquito breeding and population displacement.

Frequently Asked Questions

Sources & Citations

Related Diseases